

# Power and sample size calculations

Patrick Breheny

September 24

# Introduction

- Last time we discussed testing whether two groups differ with respect to survival/hazard
- One reason such tests are useful is that they provide an objective criteria (statistical significance) around which to plan out a study: How many subjects do we need? How long will the study take to complete? This is our topic for today
- FYI: Our book doesn't really address this issue; today's lecture is largely derived from George and Desu (1974)'s classic paper on the subject

# Exponential approximation

- The main idea behind George & Desu's approach is to assume constant hazards (i.e., exponential distributions) for the sake of simplicity
- Further work by other authors has indicated that the power/sample size one obtains from assuming constant hazards is fairly close to the empirical power of the log-rank test, provided that the ratio between the two hazard functions is constant
- Typically in a power analysis, we are simply trying to find the approximate number of subjects required by the study, and many approximations/guesses are involved, so using formulas based on the exponential distribution is often good enough

## Special case: No censoring

- Let us begin with the special case of no censoring
- If  $T_i \stackrel{\text{i.i.d.}}{\sim} \text{Exp}(\lambda)$  for  $i = 1, \dots, d$ ,

$$\begin{aligned}L(\lambda) &= \prod_i \lambda \exp(-\lambda t_i) \\ &= \lambda^d \exp(-\lambda V),\end{aligned}$$

where  $V = \sum_i t_i$

- Note that
  - $V$  is a sufficient statistic
  - $V \sim \Gamma(d, \lambda)$

## Type 2 censoring

- Now let's consider what happens in the case of type II censoring: in particular, that we have an initial sample size  $n$  and follow  $d$  subjects to failure
- In this case,

$$T_{(1)} \sim \text{Exp}(n\lambda)$$

$$T_{(2)} - T_{(1)} \sim \text{Exp}((n-1)\lambda)$$

...

$$T_{(j)} - T_{(j-1)} \sim \text{Exp}((n-j+1)\lambda)$$

for  $j = 1, \dots, d$ , with  $T_{(0)} = 0$

# Normalized spacings

- Alternatively, let  $U_j = (n - j + 1)(T_{(j)} - T_{(j-1)})$
- Now  $U_j \stackrel{\text{i.i.d.}}{\sim} \text{Exp}(\lambda)$ , and

$$\begin{aligned}L(\lambda) &= \prod_j \lambda \exp(-\lambda u_j) \\ &= \lambda^d \exp(-\lambda V),\end{aligned}$$

where  $V = \sum u_j$

- Note that, once again,  $V$  is a sufficient statistic and follows a  $\Gamma(d, \lambda)$  distribution

## Remarks

- The exponential distribution, therefore, has the somewhat remarkable property that we arrive at the exact same inference if we follow  $d$  subjects until all have failed or if we follow some larger number  $n$  until  $d$  have failed
- Thus, we can carry out our calculations ignoring censoring, provided that we think of the sample size we obtain as the number of *events* that must be observed in order to achieve the desired power
- This is incredibly convenient for sample size planning, as it allows one to completely separate treatment effect concerns from censoring concerns

## Exact vs. approximate results

- Note that because the exact distribution of  $V$  is known and easy to work with, it is possible to carry out exact power and sample size calculations
- However, one can obtain much simpler, closed-form expressions through a normal approximation
- Personal opinion: In an actual data analysis, exact results are quite desirable, but in a power analysis, the inaccuracy of the approximation is typically a minor concern compared to all other potential sources of error that go into the calculation



# Central limit theorem

- The exponential distribution has mean  $1/\lambda$  and variance  $1/\lambda^2$
- Thus, by the central limit theorem,

$$\bar{X} \sim N\left(\frac{1}{\lambda}, \frac{1}{n\lambda^2}\right)$$

- This result, however, is not particularly satisfactory due to the  $\lambda$  term in the variance, which means we will have to solve a nonlinear equation to determine power/sample size

# Log transform

- Consider instead the variance-stabilizing transformation  
 $g(x) = \log(x)$
- By the delta method,

$$\log \bar{X} \sim N\left(-\log \lambda, \frac{1}{n}\right)$$

- In addition to the convenience of linearity, variance-stabilizing transformations also typically lead to more accurate normal approximations

## Two samples: Hazard ratio

- With these preliminaries out of the way, let's get to the actual business of comparing two samples
- Let  $X_i \stackrel{\text{i.i.d.}}{\sim} \text{Exp}(\lambda_1)$  and  $Y_i \stackrel{\text{i.i.d.}}{\sim} \text{Exp}(\lambda_2)$ , with  $X_i \perp\!\!\!\perp Y_i$
- We have

$$\log \left( \frac{\bar{Y}}{\bar{X}} \right) \sim N \left( \log \Delta, \frac{1}{n_1} + \frac{1}{n_2} \right),$$

where  $\Delta = \lambda_1/\lambda_2$  is the hazard ratio

## Power formula

- Thus, letting  $Z = \log(\bar{Y}/\bar{X})/\sqrt{1/n_1 + 1/n_2}$ , we have

$$\text{Under } H_0 : Z \sim N(0, 1)$$

$$\text{Under } H_A : Z \sim N(0, 1) + \frac{\log \Delta}{\sqrt{\frac{1}{n_1} + \frac{1}{n_2}}}$$

- The critical value for  $Z$  is therefore  $CV = \Phi^{-1}(1 - \alpha/2)$ , where  $\alpha$  is the type I error rate and  $\Phi$  is the CDF of the standard normal distribution
- Without loss of generality, we can take  $\Delta > 1$ , which yields

$$\text{Power} = 1 - \Phi \left( CV - \log \Delta / \sqrt{1/n_1 + 1/n_2} \right)$$

# Sample size formula

- In order to solve for the sample size(s) that yield a power of  $1 - \beta$ , we must solve for the values of  $n_1$  and  $n_2$  that satisfy the following equation:

$$z_{1-\alpha/2} = -z_{1-\beta} + \log \Delta / \sqrt{1/n_1 + 1/n_2},$$

where  $z_q$  is the  $q$ th quantile of the standard normal distribution

- In the special case of  $n = n_1 = n_2$ , we therefore have

$$n = 2 \left( \frac{z_{1-\alpha/2} + z_{1-\beta}}{\log \Delta} \right)^2$$

as the per-group sample size

## Remarks

- Note that we do not even need to specify  $\lambda_1$  and  $\lambda_2$  to calculate power and sample size: we only need their ratio,  $\Delta$
- Furthermore, note that for the exponential distribution, the median survival time is  $\lambda^{-1} \log 2$
- Thus, the effect size can be equivalently thought of as a ratio of median survival times, rather than a hazard ratio, which in my experience is convenient as non-statisticians typically prefer to think in terms of median survival times than hazards

# NSCLC study: Background

- To illustrate how these formulas are used in practice, I'll discuss the planning of a study at the Holden Cancer Center here at the University of Iowa that I was involved in
- The study was looking at progression-free survival (PFS) in patients with refractory non-small cell lung cancer
- Historically, the median PFS for these patients is around 2.5 months
- The investigators hypothesized, however, that a novel combination of protein kinase inhibitors and a cytokines could extend PFS by 50%

# Sample size

- A 50% increase in median PFS corresponds to  $\Delta = 1.5$
- Thus, to achieve 80% power under 5% type I error rate control (these are typical numbers), we require

$$\begin{aligned}n &= 2 \frac{(1.96 + 0.84)^2}{(\log(1.5))^2} \\ &= 95.5\end{aligned}$$

events in each arm of the study

- The actual study, however, was only a “single-arm” study



# Single arm study

- In a single-arm study, one assigns all patients to the experimental therapy, with the intention of comparing it to historical controls
- The use of historical controls is clearly subject to all sorts of biases, and a randomized trial would be preferable
- However, single arm studies like this one are common in what is called “Phase II” of clinical trial research
- The goal of a Phase II study is to learn about the clinical efficacy of a treatment; if it appears promising, one would then continue on to a fully randomized trial in Phase III
- Note that for a single-arm study (treating the control group as a known constant), the number of events in the experimental arm is cut in half (i.e., the total sample size is cut by 3/4)

## Censoring and accrual

- In this study, since these are patients with very poor prognosis and a median PFS of only 2.5 months (or  $\approx 4$  months, if the treatment is effective), we anticipated that only a small fraction of patients would remain censored at the end of the study
- Specifically, we made an assumption of 20% censoring, and included the following language in the proposal:

*Power calculations indicate that to achieve 80% power to detect a 50% increase in median PFS with a 5% type I error rate, 48 events must be observed. Allowing for a 20% censoring rate, we therefore plan to enroll 58 patients.*

# Study duration

- The duration of a study is also an important concern in planning a study with a time-to-event outcome
- In the NSCLC study, the accrual rate was anticipated to be approximately 50 patients per year
- We therefore made the conservative estimate that we could enroll our 58 patients in 18 months, and that we should be able to conclude the whole study within 2 years

# Formal approach

- But is this really an adequate amount of time in which to observe 48 events?
- To address this question, let's work through how to calculate the expected duration of a study
- To start, let  $(0, T]$  denote the “entry” or “accrual” period of the study, and  $(T, T + \tau]$  denote the follow-up period


## Formal approach (cont'd)

- One widely used approach (which is also the approach used by George & Desu) is to use the fact that the expected number of patient-years necessary to observe  $d$  events is  $d/\lambda$
- Furthermore, letting  $Y(t)$  denote the number of patient-years accumulated by time  $t$  and  $a$  denote the average accrual rate,

$$\begin{aligned}\mathbb{E}Y(t) &= a \int_0^{t^*} \int_0^{t-v} S(u) du dv \\ &= \frac{at^*}{\lambda} \left\{ 1 - (\lambda t^*)^{-1} e^{-\lambda t} (e^{\lambda t^*} - 1) \right\}\end{aligned}$$

where  $t^* = \min(T, t)$

# NSCLC study duration: Accrual 50 / year



# 50 random instances at 50 / year, $T = 1.5$

